The 2012-2013 Genomics in Medicine Lecture Series
This five-lecture series by top experts in genomics will enhance health-care professionals' understanding of the intersection between genomics and medicine. The series is sponsored by the National Human Genome Research Institute (NHGRI), in collaboration with Suburban Hospital and Johns Hopkins University School of Medicine. Each lecture takes place at Suburban Hospital's lower level auditorium at 8600 Old Georgetown Road in Bethesda, Md. All are welcome to the hour-long lectures, which begin at 8 a.m. on the first Friday of the month. Advanced registration is not required; however, those requesting continuing medical education (CME) credits are asked to sign in.Lectures are recorded and posted on GenomeTV, NHGRI's YouTube channel at a later date.
March 1, 2013
Tristan Sissung, Ph.D., M.S.
Staff Scientist, National Cancer Institute (NCI), National Institutes of Health (NIH)
Currently, the NIH Clinical Center has implemented pharmacogenetics testing in patients receiving certain medications. This lecture will summarize the basis of pharmacogenetics and its use in clinical medicine and drug development. Dr. Sissung earned a Ph.D. in genetics from The George Washington University and is a staff scientist in the Clinical Pharmacology Program, NIH Clinical Center at NCI. Dr. Sissung's research focus is molecular genetics and translational pharmacogenetics.
- To review the molecular and physiological basis for gene-drug interactions.
- To appreciate the impact on drug therapy.
- To discuss the future of pharmacogenetics in drug development and treatment.
February 8, 2013
Paul A. Sieving, M.D., Ph.D.
Director of the National Eye Institute, NIH
The elucidation of the full sequence human genome in 2001 has led to identifying many of the genes that cause ophthalmic diseases, of both single gene Mendelian traits and common complex disorders. Gene identification has led to dissecting molecular mechanisms and biological pathways of disease, and these studies have provided remarkable opportunities to explore targeted therapies. Examples will be discussed of translational studies underway, including by gene transfer, biomolecules and small molecules.
- To review history of ophthalmic disease gene discovery.
- Explore various phenotypes of ophthalmic disease.
- To consider the impact of gene discovery on ophthalmic disease treatment.
January 4, 2013
Kenneth Fischbeck, M.D.
NIH Distinguished Investigator, Neurogenetics Branch, National Institute of Neurological Disorders and Stroke
Adjunct Investigator, NHGRI
Identification of hereditary neuromuscular disease genes over the past 25 years has brought accurate diagnostic testing, cell culture and animal models for studies of disease mechanisms, and opportunities for developing treatment. For diseases such as muscular dystrophy and spinal muscular atrophy, treatments have been developed that are very effective in animal models. The challenge now is to translate these findings into safe and effective therapy in patients.
- To understand the genetic causes Duchenne muscular dystrophy and spinal muscular atrophy.
- To gain insight into the mechanisms of these and other hereditary neuromuscular diseases.
- To appreciate the prospects for effective treatment for these diseases.
December 7, 2012
Ellen Sidransky, M.D.
Senior Investigator, Medical Genetics Branch, NHGRI
Head, Molecular Neurogenetics Section, NHGRI
While in the past Parkinson disease was not considered an inherited disorder, in recent years different Parkinson genes and genetic risk factors have been identified. Increasingly, the boundaries between what are considered to be common complex disorders like Parkinson disease and "simple" Mendelian disorders have become blurred. We will discuss how insights from the study of the rare lysosomal storage disorder Gaucher disease have provided a deeper understanding of the pathogenesis of Parkinson disease, and may lead to new therapeutic strategies.
- Discuss how genes implicated in Parkinson disease provide insights into the biology of the disorder.
- Explain how studies of rare diseases can provide an important window into more common complex disorders.
- Introduce the concepts of genetic risk factors and genetic modifiers and how they contribute to the overlap between Mendelian and complex disorders.
November 2, 2012
Maximillian Muenke, M.D.
Chief and Senior Investigator, Medical Genetics Branch, NHGRI
Attention Deficit Hyperactivity Disorder (ADHD) is the most common behavioral disorder of school-age children. Understanding the causes of ADHD will help identify the best treatment modality for each person with ADHD. Genomic studies in large families with ADHD have identified genetic contributions to ADHD as a first step towards personalized medicine.
- To review the impact of the clinical and behavior findings of ADHD on the individual.
- To appreciate the genetic and environmental causes of ADHD.
- To consider the impact of genomics on understanding causes and the impact on treatment.
September 7, 2012
Daniel Kastner, M.D., Ph.D.
NIH Distinguished Investigator
Scientific Director, Division of Intramural Research, NHGRI
Senior Investigator Medical Genetics Branch, NHGRI
The systemic autoinflammatory diseases are a relatively recently recognized group of disorders characterized by seemingly unprovoked inflammation, without the high titer autoantibodies or antigen-specific T-lymphocytes seen in autoimmune diseases. This talk will describe the clinical features of the autoinflammatory diseases, and will present some of the recent advances in understanding their genetics, pathophysiology, and treatment.
- Recognize salient clinical features of the Mendelian autoinflammatory diseases.
- Describe how molecular genetic strategies advance our understanding of inflammation.
- Discuss the role of interleukin-1 inhibitors in the treatment of autoinflammatory diseases.
Last Updated: March 1, 2013
Leave a Comment!
We encourage you to share your thoughts as they relate to the topics being discussed on genome.gov, other websites or discussion forums owned or administered by the National Human Genome Research Institute (NHGRI). We review all comments for posting. We do not discriminate against any views, but we reserve the right not to post comments, or to remove comments, that are inconsistent with our Comment Policy, at our complete discretion.
No comments yet. Be the first!